Bausch Health Companies (BHC)

Overall impact
C (49)

Commentary

Bausch Health Companies is an average overall performer. With a 'C' rating of 55.1 for overall impact (52nd percentile compared to all companies), Bausch Health Companies ranks 187th out of 229 industry peers, behind Avadel Pharmaceuticals, Nanoviricides, Recordati Industria Chimica E Farm and 183 others, and ahead of Collegium Pharmaceutical, Sun Pharmaceutical Industries, Mayne Pharma and 39 others. On top material causes for Bausch Health Companies's industry (Pharmaceuticals), Bausch Health Companies performs well in Disease Eradication (96.0 score), Disaster Readiness and Effective Aid (95.1), Access to Affordable Healthcare (95.3) and 6 other causes where it received an 'A' score and performs poorly in Reduced Use of tobacco (0.0 score), Reduced Use of tobacco (0.0), Reduced Inequality (25.7) and 24 other causes where it received a 'D' or 'F' score.
Impact
Cause BHC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
20,300
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Qc, Canada
Share classes
BHC
Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, developing, manufacturing, and marketing a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Material causes
Ethos considers the following causes material for Bausch Health Companies, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.